CN115804801A - Application of Terminalia catappa extract in skin conditioning and inflammation resistance - Google Patents
Application of Terminalia catappa extract in skin conditioning and inflammation resistance Download PDFInfo
- Publication number
- CN115804801A CN115804801A CN202211121542.5A CN202211121542A CN115804801A CN 115804801 A CN115804801 A CN 115804801A CN 202211121542 A CN202211121542 A CN 202211121542A CN 115804801 A CN115804801 A CN 115804801A
- Authority
- CN
- China
- Prior art keywords
- skin
- extract
- terminalia catappa
- terminalia
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
An application of Terminalia catappa (Terminalia catappa) extract in conditioning skin and resisting inflammation relates to an application of Terminalia catappa extract in preparing a composition for resisting acne, bacteria and inflammation or improving skin texture.
Description
Technical Field
The invention relates to an application of Terminalia catappa extract in conditioning skin and resisting inflammation, in particular to an application of Terminalia catappa extract in preparing a composition for resisting acne, bacteria and inflammation or improving skin texture.
Background
Since the development of organic and/or natural dietary concepts, biotechnology companies and food manufacturers have actively invested in the development of products related to natural plants. In order to enable plant-related products to have a scientific verification basis for body health help, the analysis of active ingredients and the evaluation of efficacy of plants become key projects for product development.
Terminalia catappa (Terminalia catappa) is a special plant unique to tropical islands, is a deciduous tree, and has the plant height of about 15-25 m. Before falling off in autumn or winter, leaf of Terminalia catappa turns yellow, brown or purple. The Terminalia gymnorrhiza has high tolerance to the external environment, and has strong drought resistance, wind resistance and salt resistance, so that the Terminalia gymnorrhiza is very suitable for growing on tropical islands of sandy soil which are wet at high temperature and have sufficient light. Also, the mature yellow, brown or red terminalia gigantea leaves contain a very high amount of tannic acid. Therefore, the biotechnology companies and food manufacturers actively research the analysis of active ingredients and the evaluation of efficacy of Terminalia catappa and develop related products accordingly.
Disclosure of Invention
In some embodiments, use of an extract of Terminalia catappa for the preparation of an anti-acne composition.
In some embodiments, the Terminalia catappa extract is used to reduce acne caused by skin inflammation.
In some embodiments, the Terminalia catappa extract reduces pox production by improving the skin's purpuria.
In some embodiments, the Terminalia catappa extract improves skin purpura by inhibiting and/or reducing Propionibacterium acnes.
In some embodiments, the Terminalia catappa extract is used to inhibit and/or reduce the amount of skin oils.
In some embodiments, terminalia sericea extract reduces acne scar residue by inhibiting melanogenesis.
In some embodiments, use of an extract of Terminalia catappa for preparing an antimicrobial composition.
In some embodiments, the Terminalia catappa extract is used to inhibit and/or reduce Propionibacterium acnes.
In some embodiments, use of an extract of Terminalia catappa for preparing an anti-inflammatory composition.
In some embodiments, the Terminalia catappa extract is used to inhibit keratinocyte inflammation.
In some embodiments, use of an extract of Terminalia catappa for preparing a composition for enhancing skin texture.
In some embodiments, terminalia catappa extract is used to improve skin radiance.
In some embodiments, the Terminalia catappa extract is used to reduce skin blemishes.
In some embodiments, the Terminalia catappa extract is used to reduce skin redness.
In some embodiments, the Terminalia catappa extract is used to inhibit melanogenesis.
In some embodiments, the above mentioned Terminalia catappa extract is obtained by extracting Terminalia catappa leaves with a solvent.
In some embodiments, the above mentioned terminalia hydrangea leaves are red terminalia hydrangea leaves.
In summary, the use of the Terminalia catappa extract for conditioning skin and resisting inflammation in any embodiment relates to the use of the Terminalia catappa extract for preparing an anti-acne, antibacterial, anti-inflammatory or skin texture-improving composition, so as to provide a composition capable of producing an anti-acne, antibacterial, anti-inflammatory or skin texture-improving effect on a subject when applied to the subject. In other words, the composition has the functions of anti-acne, anti-bacterial, anti-inflammation or improving the texture of skin. In some embodiments, the composition prepared from the Terminalia catappa extract further has one or more of the following functions: reducing acne caused by skin inflammation, reducing acne formation by improving skin purpura, inhibiting and/or reducing skin lipid, reducing acne scar residue by inhibiting melanin formation, inhibiting and/or reducing Propionibacterium acnes, inhibiting keratinocyte inflammation, improving skin luster, reducing skin blotch, reducing skin redness, and inhibiting melanin formation. In some embodiments, the composition prepared from Terminalia catappa extract can improve skin purpura by inhibiting and/or reducing Propionibacterium acnes.
Drawings
FIG. 1 is a bar graph of the results of cellular experiments with respect to the amount of IL-8 secretion.
FIG. 2 is a bar graph of the results of cellular experiments with respect to melanin content.
FIG. 3 is a bar graph of the results of human experiments with relative rhodopsin content before and 15 minutes after use.
Fig. 4 is a bar graph of the results of human experiments on relative skin shine before and after 15 minutes of use.
Fig. 5 is a bar graph of human experimental results of relative skin oil content before and after 8 hours of use.
FIG. 6 is a bar graph of the results of human experiments with relative rhodopsin content at week 0 and week 4.
Fig. 7 is a bar graph of the results of the human experiment showing the degree of relative redness of skin at week 0 and week 4.
Fig. 8 is a bar graph of the results of the human experiment on the degree of skin spots at week 0 and week 4.
Detailed Description
Some embodiments of the present disclosure will be described below. The present disclosure may be embodied in many different forms without departing from the spirit thereof, and the scope of protection should not be limited to the details set forth in the specification.
As used herein, the unit of content used in reference to content "percent" generally refers to weight percent.
In some embodiments, the Terminalia catappa extract is obtained by performing an extraction procedure on Terminalia catappa (Terminalia catappa).
In some embodiments, the extracted Terminalia catappa can be a plant, root, stem, leaf, or flower of Terminalia catappa. In some embodiments, the Terminalia catappa that is subjected to extraction is a yellow Terminalia catappa leaf, a brown Terminalia catappa leaf, or a red Terminalia catappa leaf. In some embodiments, the Terminalia catappa that is subjected to extraction may be a ripe to yellow Terminalia catappa leaf, a ripe to brown Terminalia catappa leaf, or a ripe to red Terminalia catappa leaf. For example, in the extraction procedure, red leaves of Terminalia mukul are extracted with a solvent. In some embodiments, the extracted Terminalia gymnorrhiza kernels can be fallen leaves.
In some embodiments, the extracted Terminalia gymnorrhiza may be used as a raw material (e.g., whole red leaves) or may be physically processed to break down into small-sized pieces, granules, or powders. The physical pre-treatment employed may include at least one of: coarse crushing, chopping, shearing, mashing, and grinding.
In some embodiments, the extracted Terminalia catappa may be freshly picked and collected, dried Terminalia catappa, or frozen Terminalia catappa during the extraction process. For example, in the extraction procedure, the dried Terminalia gymnorrhiza fruit is extracted with a solvent.
In some embodiments, in the extraction procedure, the Terminalia gymnorrhiza kernels are extracted with water at 70-100 ℃ for 1-3 hours to obtain a primary extract. For example, the Terminalia mukurossi Kerr can be soaked in water at 85 ± 5 ℃ for 60 minutes to dissolve the effective components in the Terminalia mukurossi Kerr into water to obtain the primary extract.
In some embodiments, the weight ratio of water to Terminalia catappa is 15-30. For example, the weight ratio of water to Terminalia gymnorrhiza kernel is 15. In other embodiments, the weight ratio of water to Terminalia mukul is 30.
In some embodiments, the primary extract may be further filtered to remove solids such as water extracted Terminalia gymnorrhiza to obtain a filtrate. For example, the primary extract may be filtered through a 400 mesh screen to remove solids, and the filtered filtrate collected.
In some embodiments, the filtrate may be further concentrated during the extraction procedure to provide a concentrated solution. In some embodiments, the filtrate may be concentrated under reduced pressure at 45 ℃ to 70 ℃ to obtain a concentrated solution. For example, the filtrate may be concentrated under reduced pressure at 60 ℃ ± 5 ℃. In some embodiments, the length of time for concentration may be determined by, but is not limited to, the Brix value of the concentrate (Degrees Brix;. Degree Bx). As in the previous example, the Brix value of the resulting concentrate was 3. + -. 0.5. In other words, the filtrate can be concentrated under reduced pressure at 60 ℃. + -. 5 ℃ until the filtrate after reduced pressure concentration has 3. + -. 0.5 ℃ Bx, and the filtrate after reduced pressure concentration is the concentrated solution at this time. In some embodiments, the initial extract may be concentrated and then filtered during the extraction process.
In some embodiments, during the extraction procedure, the concentrate can be further filtered to obtain a concentrated filtrate.
It should be understood that the primary extract, filtrate, concentrated solution or concentrated filtrate obtained from the extraction process can be used as the Terminalia gymnorrhiza extract according to actual requirements.
In some embodiments, the Terminalia sericea extract has anti-acne ability. Therefore, the Terminalia gymnorrhiza extract is suitable for preparing the anti-acne composition.
In some embodiments, the Terminalia catappa extract has the ability to reduce acne caused by skin inflammation. In other words, the Terminalia catappa extract can reduce acne caused by skin inflammation when administered to a subject. Therefore, the Terminalia catappa extract is suitable for preparing a composition for reducing pox caused by skin inflammation.
In some embodiments, the Terminalia sericea extract has the ability to reduce pox production by improving skin purpura. In other words, the Terminalia catappa extract improves the purple color of the skin of the subject and reduces the formation of pox when administered to the subject. Therefore, the Terminalia catappa extract is suitable for preparing a composition for reducing the generation of pox through improving the purpura of skin.
In some embodiments, the Terminalia catappa extract has the ability to improve the purpura by inhibiting and/or reducing Propionibacterium acnes. In other words, the Terminalia catappa extract can inhibit and/or reduce Propionibacterium acnes in a subject and improve skin purpura. Therefore, the Terminalia catappa extract is suitable for preparing a composition for improving skin purpura by inhibiting and/or reducing Propionibacterium acnes.
In some embodiments, the Terminalia catappa extract has the ability to inhibit and/or reduce the amount of skin oils. In other words, the Terminalia catappa extract inhibits and/or reduces the amount of skin oils in a subject when administered to the subject. Therefore, the Terminalia catappa extract is suitable for preparing a composition for inhibiting and/or reducing the amount of skin oil.
In some embodiments, terminalia sericea extract has the ability to reduce acne scar residue by inhibiting melanogenesis. In other words, the Terminalia sericea extract, when administered to a subject, inhibits melanogenesis in the subject and reduces acne scar residue. Therefore, the Terminalia catappa extract is suitable for preparing a composition for reducing acne scar residues by inhibiting melanin generation.
In some embodiments, the Terminalia gymnorrhiza extract has antibacterial activity. Therefore, the Terminalia catappa extract is suitable for preparing antibacterial composition.
In some embodiments, the Terminalia catappa extract has the ability to inhibit and/or reduce Propionibacterium acnes. In other words, the Terminalia sericea extract inhibits and/or reduces Propionibacterium acnes in a subject when administered to the subject. Therefore, the Terminalia catappa extract is suitable for preparing a composition for inhibiting and/or reducing propionibacterium acnes.
In some embodiments, the Terminalia catappa extract has anti-inflammatory properties. Therefore, terminalia catappa extract is suitable for preparing anti-inflammatory composition.
In some embodiments, the Terminalia catappa extract has the ability to inhibit keratinocyte inflammation. In other words, the Terminalia catappa extract inhibits keratinocyte inflammation in a subject when administered to the subject. Therefore, the Terminalia catappa extract is suitable for preparing the composition for inhibiting keratinocyte inflammation.
In some embodiments, the Terminalia catappa extract has the ability to enhance skin texture. Therefore, the Terminalia catappa extract is suitable for preparing the composition for improving the skin texture.
In some embodiments, the Terminalia catappa extract has the ability to enhance skin radiance. In other words, the Terminalia sericea extract, when administered to a subject, enhances the radiance of the skin of the subject. Therefore, the Terminalia catappa extract is suitable for preparing a composition for improving skin luster.
In some embodiments, the Terminalia catappa extract has the ability to reduce skin blemishes. In other words, the Terminalia sericea extract, when administered to a subject, reduces the amount of skin blemishes in the subject. Therefore, the Terminalia catappa extract is suitable for preparing a composition for reducing skin spots.
In some embodiments, the Terminalia catappa extract has the ability to reduce skin redness. In other words, the Terminalia sericea extract reduces redness when administered to a subject. Therefore, terminalia catappa extract is suitable for preparing a composition for reducing skin redness.
In some embodiments, the Terminalia gymnorrhiza extract has melanogenesis inhibitory activity. In other words, the Terminalia catappa extract inhibits melanogenesis in a subject when administered to the subject. Therefore, the Terminalia gymnorrhiza extract is suitable for preparing the composition for inhibiting melanin generation.
In some embodiments, the aforementioned individual may be a human.
In some embodiments, the content of the Terminalia catappa extract in the composition is 1%.
In some embodiments, the prepared composition may be a pharmaceutical composition, a food composition, a cosmetic composition, or a cosmetic composition.
In some embodiments, when the composition is a pharmaceutical composition, the pharmaceutical composition comprises an effective amount of Terminalia catappa extract. Wherein the pharmaceutical composition can be formulated in a form suitable for enteral, parenteral (parenterally), oral (oraly), or topical (topically) administration using techniques well known to those of ordinary skill in the art.
In some embodiments, the enterally or orally administered dosage form may be, but is not limited to, a lozenge (tablet), a tablet (troche), a buccal tablet (dosage), a pill (pill), a capsule (capsule), a dispersible powder (dispersible powder) or fine granules (granules), a solution, a suspension (suspension), an emulsion (emulsion), a syrup (syrup), an elixir (elixir), a slurry (slurry), or the like.
In some embodiments, parenteral or topical administration dosage forms can be, but are not limited to, injections (e.g., sterile aqueous solutions (sterie aqueous solutions) or dispersions), sterile powders (sterie powder), external preparations (external preparation), or the like.
In some embodiments, the administration of the injectate can be, but is not limited to, intraperitoneal injection (intraperitoneal injection), subcutaneous injection (subcutaneous injection), intraepidermal injection (intraepithelial injection), intradermal injection (intradermal injection), intramuscular injection (intramuscular injection), intravenous injection (intravenous injection), or intralesional injection (intraregional injection).
In some embodiments, the pharmaceutical composition containing an effective amount of Terminalia catappa extract may further comprise a pharmaceutically acceptable carrier (pharmaceutical acceptable carrier) that is widely used in pharmaceutical manufacturing technology. In some embodiments, the pharmaceutically acceptable carrier can be one or more of the following carriers: solvents (solvent), buffers (buffer), emulsifiers (emulsifying), suspending agents (suspending agent), disintegrating agents (disintegrant), disintegrating agents (disintegrating agent), dispersing agents (dispersing agent), binding agents (binding agent), excipients (excipient), stabilizers (stabilizing agent), chelating agents (chelating agent), diluents (diluent), gelling agents (gelling agent), preservatives (preserving), wetting agents (wetting agent), lubricants (lubricating), absorption delaying agents (absorption delaying agent), liposomes (liposome) and the like. The type and amount of the carrier selected for use is within the skill and routine skill of one of ordinary skill in the art. Among them, the solvent as a pharmaceutically acceptable carrier may be water, physiological saline (normal saline), phosphate Buffered Saline (PBS), or an aqueous solution containing alcohol (alcohol stabilizing aqueous solution).
In some embodiments, pharmaceutical compositions containing an effective amount of Terminalia catappa extract can be formulated into external preparations (external preparation) suitable for topical application to the skin using techniques well known to those of ordinary skill in the art. In some embodiments, external agents include, but are not limited to: creams (lotion), gels (gel), ointments (ingredient), creams (cream), patches (patch), liniments (liniment), powders (powder), aerosols (aerosol), sprays (spray), emulsions (lotion), serum (serum), pastes (paste), foams (foam), drops (drop), suspensions (suspension), ointments (salve) and bandages (bandage).
In some embodiments, when the pharmaceutical composition is an external preparation, the pharmaceutical composition can be prepared by mixing an effective amount of Terminalia catappa extract with a base (base) known to those of ordinary skill in the art.
In some embodiments, the substrate may include one or more additives (additives) selected from the group consisting of: water, alcohols (alcohols), glycols (glycols), hydrocarbons (hydrocarbons) [ such as petroleum jelly (jelly), white petrolatum (white jelly)]Waxes (wax) [ such as paraffin (paraffin) and yellow wax (yellow wax)]Preserving agents (preserving agents), antioxidants (antioxidants), surfactants (surfactants), absorption enhancers (absorption enhancers), stabilisers (stabilizing agents), gelling agents (gelling agents) [ such as
974P(
974P), microcrystalline cellulose (microcrystalline cellulose) and carboxymethyl cellulose (carboxymethyl cellulose)]Active agents (actives), humectants (humectants), odour absorbers (odor absorbents), fragrances (fragrances), pH adjusting agents (pH adjusting agents), chelating agents (chelating agents), emulsifiers (emulsifiers), occlusive agents (occulsives), softeners (emulsifiers), thickeners (thickeners), co-solvents (solvating agents), penetration enhancers (penetration enhancers), anti-irritants (anti-irritants), colorants (colorants) and propellants(propellants) and the like. The selection and amounts of such additives are within the skill and routine skill of one of ordinary skill in the art.
In some embodiments, when the composition is a food composition, the food composition comprises a specific amount of Terminalia catappa extract. Wherein the food composition is in the form of powder, granule, solution, colloid, or paste.
In some embodiments, the food composition comprising an extract of Terminalia gymnorrhiza may be a food product or a food additive (food additive).
In some embodiments, the food product containing Terminalia catappa extract may be a beverage (leafages), a fermented food (fermented foods), a bakery product (bakery products), a health food (health foods), a dietary supplement (dietary supplements), or the like. In some embodiments, the food product comprising Terminalia catappa extract may further comprise an adjuvant. For example, the adjuvant can be Maltodextrin (Maltodextrin), malic acid, sucralose, citric acid, fruit flavors, honey flavors, steviol glycosides, or combinations thereof, or the like. The type and amount of carrier selected for use is within the skill of one of ordinary skill in the art.
In some embodiments, the dietary supplement containing Terminalia catappa extract can be a flavoring, sweetener, spice, pH adjuster, emulsifier, colorant, stabilizer, or the like.
In some embodiments, when the aforementioned composition is a cosmetic composition or a care composition. In other words, the cosmetic composition or the care composition contains an effective amount of Terminalia catappa extract.
In some embodiments, the cosmetic or cosmetic composition containing Terminalia gymnorrhiza extract can be any of the following forms: lotions, gels, jellies, mud masks, lotions, creams, lipsticks, foundations, pressed powders, honey powders, make-up removers, facial cleansers, shower gels, shampoos, hair tonics, sun blocks, hand creams, nail polishes, perfumes, essences, and facial masks.
In some embodiments, the cosmetic or cosmetic composition comprising Terminalia gymnorrhiza extract may optionally further comprise an external acceptable ingredient. In some embodiments, the topical acceptable ingredient can be, for example, an emulsifier, a penetration enhancer, a softener, a solvent, an excipient, an antioxidant, or a combination thereof.
Unless otherwise specified in the following examples, the experimental procedures were carried out at room temperature (25 ℃ C. -30 ℃ C.) and atmospheric pressure (1 atm).
Example one
A. Raw materials:
1. the red leaves (origin: taiwan of china) of the dried Terminalia catappa are hereinafter referred to as Terminalia catappa leaves.
2. The secondary water is also called RO water (Reverse Osmosis) or secondary distilled water, hereinafter referred to as "water".
B. The preparation process comprises the following steps:
1. after heating the water to 85 + -5 deg.C, the Terminalia catappa leaves are added and soaked in the water at 85 + -5 deg.C for 60 minutes to form a primary extract containing solids. Herein, the weight ratio of the Terminalia catappa leaves to water is 1:15.
2. the primary extract cooled to room temperature (25-30 ℃) was filtered through a 400 mesh sieve to remove solids (i.e., extracted Terminalia catappa leaves) to obtain a filtrate.
3. Setting the temperature of a concentrator (type: rotavapor R-100; brand: BUCHI) to 60 +/-5 ℃, and then carrying out reduced pressure concentration on the filtrate by using the concentrator to obtain a concentrated solution with 3 +/-0.5 DEG Bx, namely the Terminalia sericea extract.
Example two
A. The test process comprises the following steps:
the Terminalia minalia muelleri extract prepared in example one is provided and tested by the SGS Taiwan inspection science and technology. The detection process comprises inoculating a certain amount of bacteria (2.7x10) 5 CFU/mL) of Propionibacterium acnes (Propionibacterium acnes, ATCC accession No.: 6919 After that), the Terminalia catappa extract is added and allowed to act for 30 minutes to 8 hours, and then the amount of Propionibacterium acnes after the action is measured. Wherein the addition amount of Terminalia catappa extract is 1% (v/v))。
B. And (3) test results:
please refer to table 1. The amount of the Terminalia gymnorrhiza extract prepared in example 1 was reduced by about 25.7% after 30 minutes of treatment with the addition of the original amount of Propionibacterium acnes; the amount of the Terminalia catappa extract prepared in example 1 was reduced by about 96.4% after 8 hours of addition to the amount of the original inoculated Propionibacterium acnes. In other words, the Terminalia catappa extract has 25.7% sterilization rate in 30 minutes; under the action time of 8 hours, the Terminalia gymnorrhiza extract has a sterilization rate of 96.4 percent.
TABLE 1
Therefore, the Terminalia catappa extract can reduce the amount of Propionibacterium acnes. Propionibacterium acnes is a pathogenic bacterium that causes acne or comedones. Therefore, the Terminalia catappa extract can reduce and/or reduce propionibacterium acnes, and further reduce/inhibit the generation of vaccinia (acne) or comedo. Furthermore, the rhodopsin is a metabolite of propionibacterium acnes, and thus the Terminalia catappa extract is also capable of improving the rhodopsin by inhibiting and/or reducing propionibacterium acnes.
EXAMPLE III
A. Materials and instruments:
1. cell lines: human primary dermal keratinocytes (Human primary epidermal keratinocytes) were purchased from ATCC under cell number PCS-200-011 and hereinafter referred to as HPEK-50 cells.
2. Cell culture medium: serum-free medium specific for keratinocytes (Keratinocyte-SFM), purchased from Gibco under product number 10724-011.
3. And (3) detection kit: ELISA Kit for Interleukin 8 (IL 8) purchased from Cloud-Clone Corp, product number SEA080Hu.
4. A detection instrument: enzyme immunoassay analyzer (ELISA reader) from BioTek corporation (usa).
B. The test process comprises the following steps:
1. HPEK-50 cells were plated at 5X 10 per well 4 The density of the individual cells was seeded in a 24-well culture plate containing 500. Mu.L of cell culture medium per well and cultured at 37 ℃ for 24 hours. Here, HPEK-50 cells were divided into three test groups, which were: blank group, control group and experimental group. Each set was triplicated (i.e. each set had three wells).
2. After 24 hours of culture, each group was replaced with 500. Mu.L of the experimental medium and culture was continued at 37 ℃ for 2 hours. Wherein the experimental culture medium of the blank group and the control group is the cell culture medium without a sample, and the experimental culture medium of the experimental group is the cell culture medium containing 0.0625% (v/v) of the Terminalia gymnorrhiza extract prepared in the first example.
3. The HPEK-50 cells of the control and experimental groups were irradiated in an ultraviolet radiation chamber with UVB (ultraviolet light, irradiation energy 300 mJ) for 4.99 minutes and incubated at 37 ℃ for 24 hours. A blank set of HPEK-50 cells was incubated without UVB irradiation for a further 24 hours at 37 ℃.
4. After the culture, 120. Mu.L of the test medium was taken out from each well, and the amount of IL-8 secretion from HPEK-50 cells in each group was measured using ELISA Kit for Interleukin 8 (IL 8). Here, after treating each group of the taken out experimental medium according to the protocol provided by ELISA Kit for Interleukin 8 (IL 8), absorbance (OD) at 450nm per well was measured using a enzyme immunoassay analyzer 450 Value).
C. And (3) test results:
the relative IL-8 secretion for all groups was calculated according to the following equation: relative IL-8 secretion (%) = (OD for each group) 450 Value/blank set OD 450 Value) × 100%.
Statistically significant differences in relative IL-8 secretion levels of the other groups compared to the control group were obtained by student's t-test statistical analysis. In the figures, the values for p are less than 0.05 when compared to the control groups, the values for p are less than 0.01 when compared to the control groups, and the values for p are less than 0.001 when compared to the control groups.
Please refer to fig. 1. The blank was not treated with UVB stimulation nor with the sample, so the test results in the blank represent the performance of HPEK-50 cells under normal physiological metabolic conditions. Here, in the case where the relative IL-8 secretion amount of the blank group was set to 100%, the relative IL-8 secretion amount of the control group was 117.21%, and the relative IL-8 secretion amount of the experimental group was 73.2%. That is, the relative IL-8 secretion of the control group of HPEK-50 cells was significantly increased by about 17.21% after UVB stimulation relative to the blank group; compared with the blank group, the HPEK-50 cells in the experimental group were stimulated by UVB and treated with Terminalia catappa extract, and the relative IL-8 secretion was reduced by about 26.8%. Relative to the control group, the HPEK-50 cells of the blank group were not treated with UVB stimulation nor with the sample, and their relative IL-8 secretion was significantly reduced by about 17.21%; compared with the control group, the HPEK-50 cells of the experimental group are remarkably reduced by about 44.01 percent relative to the IL-8 secretion amount after UVB stimulation and treatment by the Terminalia catappa extract.
In many organisms, IL-8 is released and initiates an inflammatory response when stimulated by an environmental stimulus (e.g., UVB), and thus the inflammatory status can be indirectly assessed by detection of IL-8.
The experimental results show that the Terminalia catappa extract can obviously reduce the IL-8 secretion amount of HPEK-50 cells promoted after UVB stimulation and also reduce the IL-8 secretion amount to be far lower than that of HPEK-50 cells under normal physiological metabolism conditions. In other words, the Terminalia catappa extract can obviously inhibit the secretion of IL-8 by keratinocytes, thereby reducing the inflammatory state of the keratinocytes.
Therefore, the Terminalia catappa extract can reduce and/or inhibit inflammation, and reduce and/or inhibit keratinocyte inflammation. The Terminalia catappa extract can also reduce and/or inhibit inflammation caused by external environmental stimulation, and further reduce/inhibit acne caused by skin inflammation. In other words, the Terminalia catappa extract has anti-inflammatory effect.
Example four
A. Materials and instruments:
1. cell line: mouse melanoma cells, purchased from ATCC, cell number 6475, hereinafter referred to as B16F10 cells.
2. Cell culture medium: DMEM (Dulbecco's modified Eagle's medium, available from Gibco, product number 12800017), 10% FBS (Total Bovine Serum, available from Gibco, product numbers 10437-028) and 1% antibiotic (available from Gibco, product numbers 15240-062) were added.
3. Kojic acid (Kojic acid), from Sigma, product number K3125.
4.1N NaOH: prepared from water and NaOH (purchased from Sigma, product number 221465).
5. Trypsin, purchased from Thermo, product number 15400054.
6. Enzyme immunoassay analyzer (ELISA reader) from BioTek corporation (usa).
B. The test process comprises the following steps:
1. B16F10 cells were plated at 1.5X 10 per well 5 The density of each was seeded in a 6-well culture plate containing 2mL of cell culture medium per well and cultured at 37 ℃ for 24 hours. Here, B16F10 cells were divided into three experimental groups, which were: blank group, kojic acid group and experimental group. Each set was triplicated (i.e. each set had three wells).
2. After 24 hours of incubation, each group was replaced with 2mL of experimental medium and incubation was continued for 48 hours at 37 ℃. Wherein the blank group of experiment culture medium is cell culture medium without kojic acid or sample; the experimental medium of the kojic acid group was a cell culture medium containing 0.125% (v/v) kojic acid, which has been widely recognized as a substance having a melanin production-reducing effect; and the experimental culture medium of the experimental group is a cell culture medium containing 0.125% (v/v) of the Terminalia sericea extract prepared in example one.
3. The experimental medium of each post-incubation group was removed and rinsed 2 times with PBS.
4. After rinsing, 200. Mu.L of trypsin was added to each well for reaction for 3 minutes. After the reaction, 6mL of cell culture medium was added to terminate the reaction. The suspension cells and cell culture medium in each well were then collected into the corresponding centrifuge tube.
5. After each centrifugal tube was centrifuged to pellet the cells, the supernatant in each centrifugal tube was removed, and the pellet cells were washed and suspended in PBS, and then repeated 2 times to obtain a cell suspension redissolved in 200 μ L PBS.
6. After freezing the cell suspension with liquid nitrogen for 10 minutes, it was left at room temperature for about 30 minutes to completely thaw.
7. After complete thawing, centrifuge tubes were centrifuged. Then, after removing the supernatant in the centrifugal test tubes, 120 μ L of 1N NaOH was added to each centrifugal test tube, and then the centrifugal test tubes were placed in a dry bath at 60 ℃ for heating for 60 minutes to dissolve melanin, so as to obtain each set of samples to be detected.
8. For each group, 100. Mu.L of a sample to be assayed was transferred to a 96-well plate, and the absorbance (OD) at 405nm per well was measured using an enzyme immunoassay analyzer 405 Value).
C. And (3) test results:
the relative melanin content of all groups was calculated according to the following formula: relative melanin content (%) = (each group OD) 405 Value/blank set OD 405 Value) × 100%.
Statistically significant differences in relative melanin content of the other groups compared to the blank group were obtained by student t-test statistical analysis. In the drawings, "x" represents a p value of less than 0.05 when compared to the blank group, "x" represents a p value of less than 0.01 when compared to the blank group, and "x" represents a p value of less than 0.001 when compared to the blank group.
Please refer to fig. 2. The blank was not treated with kojic acid or the sample, and therefore the test results in the blank represent the performance of B16F10 cells under normal physiological metabolic conditions. Here, when the relative melanin content of the blank group was set to 100%, the relative melanin content of the kojic acid group was 95.85%, and the relative melanin content of the experimental group was 82.26%. That is, B16F10 cells of the kojic acid group significantly decreased relative melanin content by about 4.15% after addition of kojic acid relative to the blank group; compared with the blank group, the content of the relative melanin of the B16F10 cells in the experimental group is remarkably reduced by about 17.74 percent after the Terminalia catappa extract is added. The B16F10 cells in the experimental group showed about 13.59% reduction in relative melanin content after addition of the Terminalia catappa extract relative to the kojic acid group.
The skin is stimulated by ultraviolet rays, thereby activating tyrosinase, further promoting melanin generation, and causing skin blackening. When the skin is in an inflamed state, ultraviolet rays are directly received to damage epidermal cells, so that tyrosinase is activated, melanin is generated, and the skin generates acne scars.
The experimental results show that the Terminalia catappa extract can obviously reduce the melanin content of B16F10 cells, and the capacity of reducing the melanin content of the Terminalia catappa extract is even better than that of kojic acid. In other words, the Terminalia sericea extract has the effect of reducing melanin content.
Therefore, the Terminalia catappa extract can inhibit melanin generation, reduce the generated melanin, and further is beneficial to reducing the melanin amount of an individual so as to improve the skin permeation and the skin whitening degree of the individual. Furthermore, the Terminalia sericea extract is also useful for reducing the generation of acne scars or the residue of acne scars by inhibiting the generation of melanin.
Example five
A. The test process comprises the following steps:
the facial mask of Terminalia catappa was applied (applied) to the face of 8 healthy adult subjects for 15 minutes before being removed and slightly rubbed on the finger to promote absorption.
Here, the Terminalia catappa facial mask contains 92.4% of water, 0.6% of menthone, 0.6% of hexanediol, 5% of 1, 3-butanediol, 0.2% of xanthan gum, 0.1% of thickener U21, 0.1% of triethanolamine and 1% of the Terminalia catappa extract prepared in the first example.
The subjects underwent skin testing before use (before application of the Terminalia catappa mask) and 15 minutes after use. The skin detection is based on different detection items, uses corresponding instruments and measurement modes to record numerical values of the facial skin and take pictures before and after 15 minutes of use. In addition, when the skin temperature and humidity are detected before use and after use for 15 minutes, the temperature and the humidity of a test area where a subject is located are consistent, so that the influence of factors such as external temperature and humidity on the skin is reduced.
The skin test items include skin purpurin (skin purpurin) and skin brightness (skin brightness).
Skin purple was measured on the facial skin of the subjects using a VISIA high-order digital skin detector (VISIA Complexion Analysis System) available from Canfield scientific, usa. Since acne bacilli secrete purpurin (acne bacilli metabolite) when growing, purpurin produces fluorescence reaction under Ultraviolet (UV) irradiation. The detector photographs the facial skin through UV light and detects the rhodopsin content of the skin to obtain a value representative of the rhodopsin content of the skin (hereinafter referred to as the "rhodopsin content value"). Here, the higher the value of the obtained rhodopsin content, the higher the rhodopsin content, the more vigorous the growth of acnes, and the more likely acne or comedo is to be generated. Then, the relative skin purple content is calculated by the following formula: relative rhodopsin content (%) = (content of rhodopsin in each group/content of rhodopsin before use) × 100%.
Skin gloss was measured on the facial skin of the subject using a skin gloss measuring Probe Glossimeter GL200 (C + K Multi Probe Adapter System, germany) from Courage + Khazaka electronic, inc. The probe is calculated by using direct reflection and scattered reflection of light irradiated to the skin surface to obtain a numerical value (hereinafter referred to as a skin gloss value) representing the degree of skin gloss. Here, the higher the obtained skin gloss value, the higher the skin gloss. Then, the relative skin gloss is calculated by the following formula: relative skin gloss (%) = (skin gloss value/skin gloss value before use for each group) × 100%.
B. And (3) test results:
statistically significant differences between the test results before and after 15 minutes of use were obtained by student's t-test statistical analysis. In the drawings, the term "p" means a p value of less than 0.05 when compared to before use, the term "p" means a p value of less than 0.01 when compared to before use, and the term "p" means a p value of less than 0.001 when compared to before use.
1. Test result of "purple skin")
Reference is made to fig. 3. The relative rhodopsin content of 100% was taken as the rhodopsin content value before use in 8 subjects. The average relative rhodopsin content of the subjects after 15 minutes of application of the Terminalia catappa mask (after 15 minutes of application) was 87.5%. In other words, the relative rhodopsin content of these subjects was reduced by 12.5% after 15 minutes using a facial mask of Terminalia mukurossi containing 1% of Terminalia mukurossi extract compared to before use. Rhodopsin is a metabolite of acnes and, when the amount of acnes metabolite is greater, comedones and/or acne grow more easily. Therefore, the Terminalia catappa extract can improve the skin purpura and further reduce the acne or comedo generation of the subjects. In other words, the Terminalia catappa extract can inhibit and/or reduce the occurrence of pox (acne) or comedo by improving the skin purpura.
2. Results of measurement of "skin gloss
Refer to fig. 4. The skin shine values of 8 subjects before application of the Terminalia catappa mask (before application) were taken as 100% relative skin shine. At this time, the average relative skin gloss of the subjects was 108.8% after 15 minutes of application of the Terminalia catappa mask (after 15 minutes of application). In other words, the skin gloss level of the subjects was increased by 8.8% after 15 minutes compared to that before application, using a facial mask containing 1% of Terminalia catappa extract. Therefore, the Terminalia catappa extract can really increase skin luster and improve the skin condition of a subject, namely, the Terminalia catappa extract can improve the skin luster, make the skin of the subject transparent and bright and further improve the skin texture.
Example six
A. The test process comprises the following steps:
8 healthy adult subjects were allowed to use the same amount of placebo serum and Terminalia sericea serum once on the left and right cheeks, respectively, and slightly rubbed on the finger abdomen to promote absorption. Here, the cheek side using the placebo essence was the control group, and the cheek side using the Terminalia muelleri essence was the experimental group.
Wherein the placebo essence comprises 93.4% water, 0.6% menthone, 0.6% hexanediol, 5%1, 3-butanediol, 0.2% xanthan gum, 0.1% thickener U21, and 0.1% triethanolamine.
The olive kernel essence comprises 92.4% of water, 0.6% of menthone, 0.6% of hexanediol, 5% of 1, 3-butanediol, 0.2% of xanthan gum, 0.1% of thickener U21, 0.1% of triethanolamine and 1% of the olive kernel extract prepared in the first step.
Also, the subjects were subjected to skin examination before use (face was cleaned) and 8 hours after use, respectively. Here, the skin test item is skin oil (skin oil). In addition, whether the skin care product is used before or after 8 hours, the temperature and the humidity of a test area where a subject is located are consistent during detection, so that the influence of factors such as external temperature and humidity on the skin is reduced.
The skin oil content was measured using a skin oil content measuring probe available from Courage + Khazaka electronic Co., germany
SM815 (C + K Multi Probe Adapter System, germany) the left and right cheeks of the subjects were examined before use and after 8 hours of use. The probe uses the principle of brightness meter, firstly uses the test paper in the probe to absorb the skin oil, then calculates a numerical value (hereinafter referred to as skin oil content value) representing the oil content of the skin according to the light transmission degree of the test paper. Also, the higher the value of the obtained skin oil content, the higher the skin oil content. Then, the relative skin oil content is calculated according to the following formula: relative skin oil content (%) = (amount of oil content in each group of skin/amount of oil content in skin before use) × 100%.
B. And (3) test results:
refer to fig. 5. The skin oil content measured before use in 8 subjects was taken as the relative skin oil content of 100%. At this time, after 8 hours of use, the average relative skin oil content of the experimental group (i.e., the cheek on the side using the olive kernel essence) was 64.2%, and the average relative skin oil content of the control group (i.e., the cheek on the side using the placebo essence) was 121.9%. In other words, the relative skin oil content of these subjects was reduced by 35.8% after using the olive marc essence containing 1% of the olive marc extract for 8 hours compared to before use. Moreover, compared with the 8-hour placebo essence, the use of 1% of Terminalia catappa extract in the Terminalia catappa essence can reduce the relative skin oil content of the subjects by 57.7% after 8 hours. Therefore, the Terminalia catappa extract can actually reduce skin grease and improve the skin condition of a subject, namely the Terminalia catappa extract has the effects of inhibiting and/or reducing the skin grease amount and controlling oil so as to improve the face oil condition of the subject and further achieve the anti-acne effect.
Example seven
A. The test process comprises the following steps:
8 healthy adult subjects were allowed to use the same amount of placebo serum and Terminalia mugwort essence once a day earlier and later on the left and right cheeks, respectively, for 4 consecutive weeks (i.e., 28 days). Here, the cheek side using the placebo essence was the control group, and the cheek side using the Terminalia muelleri essence was the experimental group.
Wherein the placebo concentrate comprises 93.4% water, 0.6% jasminodone, 0.6% hexylene glycol, 5%1, 3-butylene glycol, 0.2% xanthan gum, 0.1% thickener U21 and 0.1% triethanolamine.
The olive kernel essence comprises 92.4% of water, 0.6% of menthone, 0.6% of hexanediol, 5% of 1, 3-butanediol, 0.2% of xanthan gum, 0.1% of thickener U21, 0.1% of triethanolamine and 1% of the olive kernel extract prepared in the first step.
The subjects performed skin tests before the start of use (when the face was clean but the serum had not been used, hereinafter, week 0) and after 28 days of use (after the last serum was used and the face was clean, hereinafter, week 4). The skin detection is based on different detection items, uses corresponding instruments and measurement modes to record numerical values of the facial skin and take pictures before and after use. Skin test items were skin purpurin (skin purple), skin reddening (skin red) and skin spot (skin spot). In addition, in the detection process, the temperature and the humidity of the test area where the subject is located are consistent no matter in week 0 or week 4, so that the influence of factors such as external temperature and humidity on the skin is reduced.
The rhodopsin line was measured on the left and right cheeks of the subject at weeks 0 and 4 using a VISIA high-order digital skin texture tester (VISIA Complexion Analysis System) available from Canfield scientific, usa. Since acnes bacteria secrete purpurins (acnes metabolites) during growth, they fluoresce when irradiated with Ultraviolet (UV) light. The detector photographs the facial skin through UV light and detects the rhodopsin content of the skin to obtain a value representative of the rhodopsin content of the skin (hereinafter referred to as the "rhodopsin content value"). Moreover, the higher the rhodopsin content, the more vigorous the growth of acnes, and the more likely acne or comedo is to occur. Then, the relative skin purple content is calculated by the following formula: relative rhodopsin content (%) = (content of rhodopsin in each group/content of rhodopsin before use) × 100%.
Skin redness was measured on the left and right cheeks of the subject using a VISIA high-order digital skin detector at weeks 0 and 4. The detector photographs the facial skin by using RBX polarized light technology, and detects blood vessels or hemoglobin in the deep layer of the skin to obtain a value (hereinafter referred to as skin redness degree value) representing the redness of the skin. The higher the value of the degree of redness obtained, the higher the degree of redness. Then, the relative skin redness degree is calculated by the following formula: relative skin redness (%) = (degree of redness of each group of skin/degree of redness of skin before use) × 100%.
Skin spots were measured on the subject's left and right cheeks at week 0 and week 4 using a VISIA high-order digital skin tester. The instrument captures a high-resolution skin image through visible light (white light), and analyzes the image according to the number and area of the pigment spots visible to the naked eye with a built-in software to obtain a value (hereinafter referred to as skin spot degree value) representing the skin spot condition. The higher the obtained skin spot level value is, the higher the skin spot level is. Then, the relative skin spot degree is calculated by the following formula: relative skin blotchy degree (%) = (skin blotchy degree value/skin blotchy degree value before use for each group) × 100%.
B. And (3) test results:
1. test results for "rhodopsin" in skin
Refer to fig. 6. The rhodopsin content value at week 0 of 8 subjects was taken as the relative rhodopsin content of 100%. At this time, at week 4 (i.e., after 4 weeks of continuous use), the average relative skin purple content of the experimental group (i.e., the cheek on the side using the olive kernel essence) was 93.7%, and the average relative skin purple content of the control group (i.e., the cheek on the side using the placebo essence) was 115.2%. In other words, the relative skin purple content of these subjects was reduced by 6.3% compared to the pre-application period, after 4 weeks of continued application of the Terminalia catappa essence containing 1% of Terminalia catappa extract. Moreover, compared with the continuous use of the placebo essence for 4 weeks, the continuous use of the olive kernel essence containing 1% of the olive kernel extract for 4 weeks can reduce the relative skin purple content of the subjects by 21.5%. Therefore, the Terminalia gymnorrhiza extract can indeed improve the skin purpura and further reduce the pox (acne) or comedo generation of the subjects.
2. Test results for "skin redness
Refer to fig. 7. The skin redness value at week 0 of 8 subjects was regarded as the relative skin redness of 100%. At this time, at week 4 (i.e., after 4 weeks of continuous use), the average relative skin redness of the experimental group (i.e., the cheek on the side using the olive kernel essence) was 82.6%, and the average relative skin redness of the control group (i.e., the cheek on the side using the placebo essence) was 103.8%. In other words, the relative skin redness of these subjects was reduced by 17.4% compared to the pre-application period after 4 weeks of the long-lasting long-leaf olive essence containing 1% of the long-leaf olive extract. Moreover, compared with the continuous use of the placebo essence for 4 weeks, the continuous use of the olive leaf essence containing 1% of the olive leaf extract for 4 weeks can reduce the relative skin redness of the subjects by 21.2%. Therefore, the Terminalia catappa extract can reduce skin redness, improve the skin condition of the subject and further improve the skin texture.
3. The result of the detection of "skin spots
Refer to fig. 8. The skin spot degree value at week 0 of 8 subjects was regarded as a relative skin spot degree of 100%. At this time, at week 4 (i.e., after 4 weeks of continuous use), the average relative skin spot degree of the experimental group (i.e., the cheek on the side using the olive kernel essence) was 96.6%, and the average relative skin spot degree of the control group (i.e., the cheek on the side using the placebo essence) was 104.0%. In other words, the relative skin blotch of these subjects was reduced by 3.4% compared to the pre-application period after 4 weeks of continued application of the essence of Terminalia catappa extract containing 1% of Terminalia catappa extract. Moreover, compared with the continuous use of the placebo essence for 4 weeks, the continuous use of the olive kernel essence containing 1% of the olive kernel extract for 4 weeks can reduce the relative skin spot degree of the subjects by 7.4%. Therefore, the Terminalia catappa extract can reduce skin spots, improve the skin condition of a subject and further improve the skin texture.
In summary, the use of the Terminalia catappa extract for conditioning skin and resisting inflammation in any embodiment relates to the use of the Terminalia catappa extract for preparing an anti-acne, antibacterial, anti-inflammation or skin texture-improving composition, so as to provide a composition capable of generating anti-acne, antibacterial, anti-inflammation or skin texture-improving effects on a subject when applied to the subject. In other words, the composition has the functions of anti-acne, anti-bacterial, anti-inflammation or improving the texture of skin. In some embodiments, the composition prepared from the Terminalia catappa extract further has one or more of the following functions: reducing acne caused by skin inflammation, reducing acne formation by improving skin purpura, inhibiting and/or reducing skin lipid, reducing acne scar residue by inhibiting melanin formation, inhibiting and/or reducing Propionibacterium acnes, inhibiting keratinocyte inflammation, improving skin luster, reducing skin blotch, reducing skin redness, and inhibiting melanin formation. In some embodiments, the composition prepared from Terminalia catappa extract can improve skin purpura by inhibiting and/or reducing Propionibacterium acnes.
The present invention is capable of other embodiments, and various changes and modifications can be made by one skilled in the art without departing from the spirit and scope of the invention.
Claims (17)
1. Use of Terminalia catappa extract in preparing anti-acne composition is provided.
2. The use of claim 1, wherein the Terminalia catappa extract is used to reduce acne caused by skin inflammation.
3. The use of claim 1, wherein the Terminalia catappa extract reduces vaccinia production by improving skin purpurin.
4. The use as in claim 3, wherein said Terminalia catappa extract improves said skin purpurin by inhibiting and/or reducing Propionibacterium acnes.
5. The use as in claim 1, wherein the Terminalia catappa extract is used to suppress and/or reduce the amount of skin oils.
6. The use as claimed in claim 1, wherein the Terminalia sericea extract reduces acne scar residue by inhibiting melanogenesis.
7. Use of Terminalia catappa extract in preparing antibacterial composition is provided.
8. The use as claimed in claim 7, wherein the Terminalia catappa extract is used to inhibit and/or reduce Propionibacterium acnes.
9. Use of Terminalia catappa extract for preparing anti-inflammatory composition is provided.
10. The use as claimed in claim 9, wherein the Terminalia catappa extract is used to inhibit keratinocyte inflammation.
11. Use of Terminalia catappa (Terminalia catappa) extract in preparing composition for improving skin texture is provided.
12. The use as claimed in claim 11, wherein the Terminalia catappa extract is used to improve skin radiance.
13. The use as claimed in claim 11, wherein the Terminalia catappa extract is used to reduce skin spots.
14. The use as claimed in claim 11, wherein the Terminalia catappa extract is used to reduce skin redness.
15. The use as in claim 11, wherein said Terminalia sericea extract is used to inhibit melanogenesis.
16. The use as claimed in claim 1, 7, 9 or 11, wherein the Terminalia catappa extract is obtained by extracting Terminalia catappa leaves with a solvent.
17. The use as claimed in claim 16, wherein the Terminalia catappa leaves are red Terminalia catappa leaves.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163244266P | 2021-09-15 | 2021-09-15 | |
| US63/244,266 | 2021-09-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115804801A true CN115804801A (en) | 2023-03-17 |
Family
ID=85482598
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211121542.5A Pending CN115804801A (en) | 2021-09-15 | 2022-09-15 | Application of Terminalia catappa extract in skin conditioning and inflammation resistance |
| CN202211121740.1A Pending CN115804739A (en) | 2021-09-15 | 2022-09-15 | Fermented product of autumn plum, and its preparation method and application |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211121740.1A Pending CN115804739A (en) | 2021-09-15 | 2022-09-15 | Fermented product of autumn plum, and its preparation method and application |
Country Status (2)
| Country | Link |
|---|---|
| CN (2) | CN115804801A (en) |
| TW (2) | TWI830382B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110300592A (en) * | 2016-12-20 | 2019-10-01 | 瑞星菲尼克斯工业公司 | The product of Fei Shi olive kernel leaf extract and the extract containing Fei Shi olive kernel leaf |
| TWM614159U (en) * | 2021-04-15 | 2021-07-01 | 孟鄉生化科技股份有限公司 | Facial mask |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6689024B2 (en) * | 2013-12-27 | 2020-04-28 | 共栄化学工業株式会社 | External skin preparation |
| CN106854643B (en) * | 2015-12-08 | 2021-01-26 | 台湾粒线体应用技术股份有限公司 | Use of plant extracts for increasing mitochondrial activity |
| CN107951817A (en) * | 2017-12-21 | 2018-04-24 | 佛山市汇汾化妆品科技有限公司 | A kind of whitening wrinkle-removing facial mask of ferment containing mirabalan and preparation method |
| TWI699208B (en) * | 2018-05-25 | 2020-07-21 | 大江生醫股份有限公司 | Integrated fruits and vegetables and berries ferment, preparation method thereof and use thereof |
| TWI767168B (en) * | 2019-09-10 | 2022-06-11 | 大江生醫股份有限公司 | Use of rosa plant extract for improving mitochondrial activity |
-
2022
- 2022-09-15 TW TW111135002A patent/TWI830382B/en active
- 2022-09-15 TW TW111135003A patent/TW202313082A/en unknown
- 2022-09-15 CN CN202211121542.5A patent/CN115804801A/en active Pending
- 2022-09-15 CN CN202211121740.1A patent/CN115804739A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110300592A (en) * | 2016-12-20 | 2019-10-01 | 瑞星菲尼克斯工业公司 | The product of Fei Shi olive kernel leaf extract and the extract containing Fei Shi olive kernel leaf |
| TWM614159U (en) * | 2021-04-15 | 2021-07-01 | 孟鄉生化科技股份有限公司 | Facial mask |
Non-Patent Citations (1)
| Title |
|---|
| OVIN QONITA ALLYN1等: "Antimicrobial activity of Terminalia catappa brown leaf extracts against Staphylococcus aureus ATCC 25923 and Pseudomonasaeruginosa ATCC 27853 [version 1; referees: 2 approved, 1 notapproved]", 《F1000RESEARCH》, no. 7, pages 1 - 9 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115804739A (en) | 2023-03-17 |
| TW202313082A (en) | 2023-04-01 |
| TWI830382B (en) | 2024-01-21 |
| TW202313087A (en) | 2023-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111053716B (en) | Application of Fuzhuan tea extract in preparation of skin conditioning product | |
| CN107334726A (en) | A kind of acne-removing composition and its preparation method and application | |
| CN114099586B (en) | Application of muskmelon eggplant fermentation juice | |
| CN104487061B (en) | Composition | |
| KR20150078868A (en) | Cosmetic composition containing ginsenoside Rd, Rb2 and Bambusae Caulis in Taeniam extracts | |
| CN111067827B (en) | Composition for improving wrinkles and skin cosmetic for improving wrinkles | |
| FR2928549A1 (en) | USE OF AN EXTRACT OF BRASSOCATTLEYA MARCELLA KOSS ORCHIDEE AS AN AGENT TO PREVENT OR DELAY THE APPEARANCE OF SIGNS OF SKIN AGING | |
| JP3432175B2 (en) | Cell growth promotion cosmetics | |
| CN115804801A (en) | Application of Terminalia catappa extract in skin conditioning and inflammation resistance | |
| JP5062980B2 (en) | Moisturizer, collagen production promoter, whitening agent, antioxidant, and vascular endothelial growth factor production promoter | |
| KR102290291B1 (en) | Composition for improving moisturizing skin containing fermented blueberry and black rice extracts | |
| JP5312731B2 (en) | Topical skin preparation | |
| KR102154139B1 (en) | Composition comprising fermentation of sap of painted maple, cacao nibs extract and granat extract | |
| WO2020203933A1 (en) | Antiaging agent, antioxidant, antiinflammatory agent and whitening agent, and cosmetic | |
| KR102520908B1 (en) | Preparation of aged solution of fruit of dioscorea opposita thumb, and aged solution of fruit of dioscorea opposita thumb prepared thereby | |
| KR20110122448A (en) | Cosmetic composition comprising the extract of filipendula formosa as active ingredient | |
| JP2007277100A (en) | Humectant, cell activator, dermal fibroblast activator, epidermal cell activator, collagen production accelerator, antioxidant, anti-aging agent, beautifully whitening agent or melanin production inhibitor | |
| KR102583304B1 (en) | Composition for Anti-glycation, Whitening and Skin Condition Improvement Comprising Plant Complex Extracts as Active Ingredient | |
| KR102561258B1 (en) | Composition for controlling sebum and improving pore comprising Jasminum Officinale, Salix Alba (willow) bark and Solanum melogena fruit extract | |
| KR101131685B1 (en) | Cosmetic compositions having sebosuppressive effect | |
| CN112438922B (en) | Application of mangosteen fermentation liquor in preparation of composition for beautifying skin and/or reducing fat | |
| JP2010070501A (en) | Moisturizer, anti-aging agent, antioxidant, neutral fat-accumulation inhibitor, skin-beautifying agent, antiinflammatory agent, skin preparation for external use and peroral preparation | |
| JP2006063056A (en) | Humectant, cell-activating agent, bleaching agent and antioxidant | |
| CN115721585A (en) | Application of sesbania grandiflora extract in strengthening skin barrier and relieving skin redness | |
| KR20230087208A (en) | Korean medicinal green tea callus ferment filtrate for improving atopic dermatitis and cosmetic composition containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |